EKF Diagnostics (LON:EKF) Shares Down 7% - Time to Sell?

Key Points

• EKF Diagnostics Holdings plc's share price plummeted by 7%, trading as low as GBX 23.60 ($0.31) before slightly recovering to GBX 26 ($0.35).
• The company reported quarterly earnings with an earnings per share (EPS) of GBX 0.43 and has a market capitalization of £116.76 million.
• Shares traded at a remarkable volume of 2.28 million, surpassing the average session volume by 404%.

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s share price fell 7% during mid-day trading on Friday . The stock traded as low as GBX 23.60 ($0.31) and last traded at GBX 26 ($0.35). 2,281,890 shares traded hands during trading, an increase of 404% from the average session volume of 453,091 shares. The stock had previously closed at GBX 27.95 ($0.37).

EKF Diagnostics Stock Down 7.0%

The company has a market capitalization of £116.76 million, a P/E ratio of 19.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60. The firm's fifty day moving average is GBX 29.26 and its 200-day moving average is GBX 26.56.

EKF Diagnostics (LON:EKF - Get Free Report) last announced its quarterly earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. As a group, equities research analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.